50
Participants
Start Date
April 18, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
DA-302168S
SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 6 subjects receive DA-302168S tablets.
Placebo of DA-302168S
SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 2 subjects receive placebo of DA-302168S tablets.
DA-302168S
MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 8 subjects receive study DA-302168S tablets.
Placebo of DA-302168S
MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive study placebo of DA-302168S tablets.
Gulou Hospital Affiliated to Nanjing Medical University, Nanjing
Lead Sponsor
Chendu DIAO Pharmaceutical Group CO., LTD.
INDUSTRY